
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15b-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2025

Commission File Number: 001-41359

Belite Bio, Inc

(Exact name of registrant as specified in its charter)

Not Applicable

(Translation of Registrant's name into English)

**12750 High Bluff Drive Suite 475,
San Diego, CA 92130**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F

Form 40-F

All of the proposed resolutions as set out in Belite Bio, Inc's Notice of Annual General Meeting of Shareholders dated March 18, 2025 were duly passed at its 2025 Annual General Meeting of Shareholders held on April 15, 2025. An announcement with respect to the foregoing is attached as exhibits to this Form 6-K and is incorporated by reference herein.

This Report on Form 6-K shall be deemed to be incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933, and shall be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

[Exhibit 99.1 — Results of the 2025 Annual General Meeting of Shareholders](#)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Belite Bio, Inc

By: /s/ Yu-Hsin Lin

Name: Yu-Hsin Lin

Title: Chief Executive Officer and Chairman

Date: April 15, 2025



Belite Bio Announces Results of 2025 General Meeting

SAN DIEGO, April 15, 2025 - Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces the resolutions adopted at its 2025 general meeting of shareholders held in San Diego on April 15, 2025.

At the meeting, Belite’s shareholders approved (i) the re-election of Mr. Yu-Hsin Lin as a director of the Company; (ii) the re-election of Mr. Hao-Yuan Chuang as a director of the Company; (iii) the re-election of Ms. Wan-Shan Chen as a director of the Company; (iv) the re-election of Mr. John M. Longo as an independent director of the Company; (v) the re-election of Mr. Ita Lu as an independent director of the Company; (vi) the re-election of Mr. Gary C. Biddle as an independent director of the Company; (vii) the removal of Ms. Hung-Wei Chen as a director of the Company; and (viii) the election of Ms. Xiao-Hui Chen as a director of the Company.
